BUY
|
Original-Research: mVISE AG - from NuWays AG
Classification of NuWays AG to mVISE AG
FY24 in line as profitabilty strongly increases; chg. Topic: mVISE released a sound set of FY24 figures, were sales declined as expected but EBITDA increased thanks to the imposed efficiency measures. In detail: FY24 sales decreased by 33% yoy to € 9.3m (eNuW: € 9.4m). The reduction in sales was mainly due to the restructuring process and the continued reorganization of the business model. In this context, the company actively reduced the number of employees further. Positively, the gross margin improved by 1pp yoy to 63.9%, implying a gross profit of € 6.0m. Contrary to the top-line development, mVISE was able to improve EBITDA by 2.8% yoy to € 1.1m, implying a strong EBITDA margin improvement to 12.1% (+4.3pp yoy). This figures represents the adjusted EBITDA, where the derecognition of the at-equity investment elastic.io is not considered. Taking this into account, reported EBITDA stood at € 1.5m. The main reason for the strong profitabilty improvement was again the staff reduction, which becomes visible in significantly reduced personnel expenses (-39% yoy; -2.8pp sales ratio). In our view, this fully underpins that the change in strategy, which also includes the the discontinuation of low-margin projects in connection with the corresponding personnel measures, is clearly bearing fruit. FY25 guidance. Next to the release, management put out a new guidance for FY25, targeting an EBITDA of at least € 1.3m, thus implying a 15% yoy increase. Yet, this is significantly below our old estimate of € 2.1m, which is why we regard the outlook as conservative. On the other hand, sales should continue to decline in FY25e in the context of the ongoing restrucuring, before we will see a top-line expansion again in FY26e. Despite the rather muted FY25 outlook, the company remains fully on track with its transformation, which should become visible in continuously improving margins and returns. As this is not fully relfected in the share price in our view (i.e. FY25e EV/EBITDA of 11.3x; FY26e: 8.3x), we reiterate our BUY recommendation with a new PT of € 1.30 (old: € 1.40) based on DCF. You can download the research here: http://www.more-ir.de/d/32060.pdf For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2106408 26.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.